The UK and US have reached a major bilateral deal that will keep zero levies on UK medicine shipments going into the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that tariffs on these crucial goods will be held at nothing for a duration of the next three years.
This deal is in response to earlier warnings to dramatically increase import taxes on patented pharmaceutical products, with figures floated reaching double the cost.
"This arrangement with the Britain strengthens the global environment for innovative medicines and introduces much-needed balance to transatlantic medicine commerce," a release said.
Commercial Impact
Drugs are one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of September, the UK shipped medicines valued at £11.1bn to the US. This value represented nearly one-fifth of all goods exports in that timeframe.
"This guarantee secures work, increases funding and sets the stage for the UK to become a international leader for biotech and pharma," a government official commented.
Key British Pledges
The deal involves several notable commitments from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates were more than 20%.
Recent Tensions
This agreement comes amid a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by assertions that American consumers were paying significantly more for the same drugs than people in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been pledged toward American operations.
One official acknowledged that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a proportion of its overall budget over the past decade.
